A good DM Medical Oncology thesis uses the high volume of patients in Indian cancer centres to study toxicity, response, compliance or survival with treatments already in routine use. Prospective cohorts receiving a standard regimen, comparisons of dosing schedules and real-world outcomes of newer targeted or immunotherapy drugs are feasible within the DM course when the endpoint is response, toxicity or progression over a limited period. Supportive care questions are often the easiest to complete.
The catalogue covers Breast & Gynaecological Cancer, Palliative & Supportive Care, Haematological Malignancies, GI Malignancies, Immunotherapy & Targeted Therapy, Lung Cancer, Head & Neck Cancer and Genitourinary Cancer. Titles include cisplatin scheduling with radiotherapy, nutrition during chemoradiation, lenvatinib in thyroid cancer and PSMA PET-CT in prostate cancer. Objectives or a full synopsis can be bought for any title.
1What the DM Medical Oncology catalogue covers
Our thesis-title catalogue, shared with our sister site medicalthesistopic.in, currently lists 236 DM Medical Oncology titles. The newest ones are based on PubMed literature published in 2024–2026. Titles by subject area (top 10):
| Subject area | Titles |
|---|---|
| Breast & Gynaecological Cancer | 27 |
| Palliative & Supportive Care | 27 |
| Haematological Malignancies | 26 |
| GI Malignancies | 23 |
| Immunotherapy & Targeted Therapy | 21 |
| Lung Cancer | 18 |
| Head & Neck Cancer | 18 |
| Genitourinary Cancer | 16 |
| Sarcoma & Rare Tumours | 16 |
| Oncological Emergencies | 16 |
Most common study designs: prospective observational study (141), retrospective record-based study (39), hospital-based cross-sectional study (31), prospective comparative study (21), prospective audit (2), cross-sectional study (2). Each title already names its study design, so you can see at a glance whether it suits your department's patient load and your timeline.
250 recent DM Medical Oncology thesis titles
These 50 titles are free to read. Discuss any of them with your guide before you commit; check that it has not already been taken up in your department.
- 001
Clinical profile and outcome of adrenocortical carcinoma treated with mitotane
Sarcoma & Rare TumoursRetrospective record-based studyDescriptive Study - 002
Response and toxicity of pazopanib in advanced soft tissue sarcoma
Sarcoma & Rare TumoursProspective observational studyProspective Study - 003
Response to methotrexate and predictors of resistance in low-risk gestational trophoblastic neoplasia
Sarcoma & Rare TumoursProspective observational studyProspective Study - 004
Clinical profile and outcome of extrapulmonary neuroendocrine carcinoma
Sarcoma & Rare TumoursRetrospective record-based studyDescriptive Study - 005
Clinical profile and outcome of rhabdomyosarcoma in adults
Sarcoma & Rare TumoursRetrospective record-based studyDescriptive Study - 006
Medical management and outcome of desmoid tumours
Sarcoma & Rare TumoursRetrospective record-based studyDescriptive Study - 007
Clinical profile and outcome of mucosal melanoma treated with immunotherapy
Sarcoma & Rare TumoursRetrospective record-based studyDescriptive Study - 008
Relapse patterns and role of tumour markers during surveillance of stage I testicular germ cell tumours
Genitourinary CancerProspective observational studyProspective Study - 009
Incidence of cardiovascular events in men receiving androgen deprivation therapy for prostate cancer
Genitourinary CancerProspective observational studyProspective Study - 010
Clinicopathological profile and outcome of upper tract urothelial carcinoma
Genitourinary CancerRetrospective record-based studyDescriptive Study - 011
Prevalence of germline DNA repair gene mutations in metastatic prostate cancer
Genitourinary CancerHospital-based cross-sectional studyCross-sectional Study - 012
Clinical profile and response to chemotherapy in locally advanced and metastatic penile cancer
Genitourinary CancerRetrospective record-based studyDescriptive Study - 013
Outcome of avelumab maintenance after first-line chemotherapy in advanced urothelial carcinoma
Genitourinary CancerProspective observational studyProspective Study - 014
Impact of PSMA PET-CT on staging and management of high-risk prostate cancer
Genitourinary CancerProspective observational studyDiagnostic Study - 015
Triplet therapy with androgen deprivation, docetaxel and abiraterone in metastatic hormone-sensitive prostate cancer
Genitourinary CancerProspective observational studyProspective Study - 016
Clinicopathological profile and outcome of salivary gland malignancies
Head & Neck CancerRetrospective record-based studyDescriptive Study - 017
Outcome of lenvatinib in radioiodine-refractory differentiated thyroid cancer
Head & Neck CancerRetrospective record-based studyDescriptive Study - 018
Nutritional decline and need for enteral feeding during chemoradiation for head and neck cancer
Head & Neck CancerProspective observational studyProspective Study - 019
Weekly versus three-weekly cisplatin with radiotherapy in head and neck cancer: compliance and toxicity
Head & Neck CancerProspective comparative studyComparative Study - 020
p16 expression in oropharyngeal squamous cell carcinoma and its association with treatment outcome
Head & Neck CancerHospital-based cross-sectional studyCross-sectional Study - 021
Clinical profile and risk factors of oral cavity cancer in adults below 40 years
Head & Neck CancerProspective observational studyDescriptive Study - 022
Drug utilisation patterns and survival in recurrent or metastatic head and neck cancer in a resource-constrained setting
Head & Neck CancerRetrospective record-based studyDescriptive Study - 023
Low-dose nivolumab with metronomic chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
Head & Neck CancerProspective observational studyProspective Study - 024
Cardiovascular risk profile in breast cancer survivors after anthracycline and trastuzumab therapy
Palliative & Supportive CareHospital-based cross-sectional studyCross-sectional Study - 025
Awareness and preferences for advance care planning among patients with advanced cancer
Palliative & Supportive CareHospital-based cross-sectional studyCross-sectional Study - 026
Caregiver burden and its determinants among caregivers of patients with advanced cancer
Palliative & Supportive CareHospital-based cross-sectional studyCross-sectional Study - 027
Incidence and severity of hand-foot syndrome with capecitabine and its effect on dose intensity
Palliative & Supportive CareProspective observational studyProspective Study - 028
Prevalence and management of opioid-induced constipation in patients with cancer pain
Palliative & Supportive CareHospital-based cross-sectional studyCross-sectional Study - 029
Biosimilar pegfilgrastim as primary prophylaxis: incidence of febrile neutropenia and dose delays
Palliative & Supportive CareProspective observational studyProspective Study - 030
Prevalence and correlates of cancer-related fatigue in patients receiving chemotherapy
Palliative & Supportive CareHospital-based cross-sectional studyCross-sectional Study - 031
Olanzapine 5 mg versus 10 mg for prevention of chemotherapy-induced nausea and vomiting
Palliative & Supportive CareProspective comparative studyComparative Study - 032
Early integrated palliative care versus standard oncology care on quality of life in advanced cancer
Palliative & Supportive CareProspective comparative studyComparative Study - 033
Uptake of immunotherapy through patient assistance programmes and factors affecting access
Immunotherapy & Targeted TherapyHospital-based cross-sectional studyCross-sectional Study - 034
Prevalence of drug interactions between oral tyrosine kinase inhibitors and acid-suppressive therapy
Immunotherapy & Targeted TherapyHospital-based cross-sectional studyCross-sectional Study - 035
Tuberculosis reactivation in patients receiving immune checkpoint inhibitors in a high tuberculosis burden setting
Immunotherapy & Targeted TherapyProspective observational studyProspective Study - 036
Real-world toxicity profile of antibody-drug conjugates in metastatic breast and gastric cancer
Immunotherapy & Targeted TherapyProspective observational studyProspective Study - 037
Safety and outcome of immune checkpoint inhibitor rechallenge after immune-related adverse events
Immunotherapy & Targeted TherapyRetrospective record-based studyDescriptive Study - 038
Tumour mutational burden on next-generation sequencing and outcome with immunotherapy in advanced solid tumours
Immunotherapy & Targeted TherapyProspective observational studyDescriptive Study - 039
Incidence and predictors of hyperprogressive disease on immune checkpoint inhibitors
Immunotherapy & Targeted TherapyProspective observational studyProspective Study - 040
Baseline neutrophil-lymphocyte ratio as a predictor of response to immune checkpoint inhibitors
Immunotherapy & Targeted TherapyProspective observational studyProspective Study - 041
Low-dose versus standard-dose immune checkpoint inhibitors in advanced solid tumours: response, toxicity and cost
Immunotherapy & Targeted TherapyProspective comparative studyComparative Study - 042
Clinical profile and outcome of peripheral T-cell lymphoma
Haematological MalignanciesRetrospective record-based studyDescriptive Study - 043
Outcome of acute promyelocytic leukaemia treated with ATRA and arsenic trioxide
Haematological MalignanciesProspective observational studyProspective Study - 044
Response and tolerability of generic ibrutinib in chronic lymphocytic leukaemia
Haematological MalignanciesProspective observational studyProspective Study - 045
Clinical profile and outcome of primary CNS lymphoma treated with high-dose methotrexate-based therapy
Haematological MalignanciesRetrospective record-based studyDescriptive Study - 046
Carbapenem-resistant Gram-negative colonisation and bloodstream infection in patients with haematological malignancies
Haematological MalignanciesProspective observational studyProspective Study - 047
Treatment-free remission after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia
Haematological MalignanciesProspective observational studyProspective Study - 048
Real-world response and survival with daratumumab-based regimens in multiple myeloma
Haematological MalignanciesProspective observational studyProspective Study - 049
Measurable residual disease by flow cytometry after induction and its effect on outcome in acute lymphoblastic leukaemia
Haematological MalignanciesProspective observational studyProspective Study - 050
Response and survival with venetoclax-azacitidine in elderly or unfit patients with acute myeloid leukaemia
Haematological MalignanciesProspective observational studyProspective Study
3Download DM Medical Oncology titles in Excel (₹1 per title)
Want more than these 50? Download an Excel of the newest titles: latest 100 for ₹100, latest 500 for ₹500, or all 236 titles at ₹1 each. Or search a keyword (for example a disease or test) and pay only for the titles found. Pay by UPI, QR or card; the Excel downloads instantly.
📥 DM Medical Oncology Titles in Excel · ₹1 per title
100 titles = ₹100. Secure checkout (UPI / QR / card) on our sister site medicalthesistopic.in; the Excel downloads instantly.
1 · Speciality package (newest first)
2 · Or search a keyword
Objectives / thesis plan for a title: separate payment on medicalthesistopic.in.
Terms and Conditions · Privacy Policy · Shipping Policy · Cancellation and Refunds · Contact Us
4Objectives and synopsis for any title
Liked a title? Each one has two optional paid add-ons on medicalthesistopic.in, paid separately there:
- Objectives (₹50): research question, aim, primary and secondary objectives, hypothesis and outcome measures for that exact title.
- Full Plan / Synopsis (₹500): a complete synopsis draft for that title, from introduction and review-of-literature search plan to sample size working, methodology and statistical plan.
Use the buttons under each title above; they open that title on medicalthesistopic.in. Treat the output as a first draft to edit with your guide, and read how to write aims and objectives before you finalise yours.
5Tips for choosing a DM Medical Oncology topic
- Grade toxicity with CTCAE and response with RECIST, and record both at fixed cycles, so your results are standard and comparable with published trials and other Indian series.
- Newer targeted and immunotherapy drugs are expensive and often patient-funded or obtained through access programmes; confirm how many patients actually receive them before choosing a real-world outcome study.
- Survival endpoints need adequate follow-up; prefer response, toxicity, compliance or early progression, or use a mixed design that adds retrospective patients to a prospective cohort.
- Supportive and palliative care studies need little extra cost; use validated tools such as the Edmonton Symptom Assessment System, EORTC quality-of-life questionnaires or the Distress Thermometer.
For the general checklist (patient load, timeline, cost, ethics), see how to choose an MD/MS thesis topic. Every titles page for other specialities is listed on thesis topics by speciality.
6Need help with your thesis?
PubMedico's team helps DM Medical Oncology residents with synopsis writing, sample size, statistics and the final thesis draft. WhatsApp +91 78787 33004 for a free thesis guidance.
❓ Frequently Asked Questions
Quick answers to common questions on this topic
Yes, but plan carefully. Overall survival usually needs longer follow-up than the course allows, so many residents use progression-free survival, response rate or event-free survival at a defined point. Combining a retrospective cohort with prospective patients can increase numbers and follow-up time, provided the data quality is comparable.
Comparisons of approved drugs or schedules can be done as a randomised study with ethics approval and CTRI registration. Investigational drugs are usually outside the scope of a thesis. Real-world observational studies of standard regimens are more common and easier to complete, and they answer useful questions about Indian patients.
Head and neck, cervical, breast, gallbladder and lung cancers are common in India and offer plenty of patients. Questions about treatment tolerance in undernourished patients, financial toxicity, generic and biosimilar drug outcomes, and adherence to oral therapy are especially relevant to Indian practice and are rarely answered by Western trials.
Use them as starting points. Discuss the title with your guide, check that it fits your department's patients and facilities, check it has not already been done at your institution, and adjust the wording before you submit it to your ethics committee.
📍 Medical Thesis Help in Your City
PubMedico works with MD, MS, DNB, MDS, PhD and MSc Nursing scholars across India. Find thesis writing, statistical analysis and publication support near your college:
…and 38 more cities across India. See all locations on the home page →